Langerhans cell histiocytosis (LCH) is an inflammatory myeloid malignancy in the “L-group” histiocytosis. Mitogen-activated protein kinase (MAPK) pathway activating mutations are detectable in nearly all LCH lesions. However, the pathogenic roles of MAPK pathway activation in the development of histiocytosis are still elusive. This review will summarize research concerning the landscape and pathogenic roles of MAPK pathway mutations and related treatment opportunities in Langerhans cell histiocytosis.

中文翻译：

---

朗格汉斯细胞组织细胞增生症的信号通路、微环境和靶向治疗

朗格汉斯细胞组织细胞增生症 (LCH) 是“L 组”组织细胞增生症中的一种炎性骨髓恶性肿瘤。在几乎所有的 LCH 病变中都可以检测到丝裂原活化蛋白激酶 (MAPK) 通路激活突变。然而，MAPK 通路激活在组织细胞增多症发展中的致病作用仍不清楚。本综述将总结有关 MAPK 通路突变的概况和致病作用以及朗格汉斯细胞组织细胞增生症相关治疗机会的研究。